autogenous papilloma vaccine

An autogenous papilloma vaccine is a personalized immunotherapy prepared from a patient's own surgically excised tumor tissue. It is primarily developed for the treatment of Recurrent Respiratory Papillomatosis (RRP), particularly the juvenile-onset form, which is caused by Human Papillomavirus (HPV) types 6 and 11. The vaccine is manufactured by extracting and processing viral antigens and tumor proteins from the patient's own biopsy material, which are then re-administered to the patient to stimulate a specific cell-mediated immune response. By priming the immune system to recognize and attack HPV-infected cells, the vaccine aims to reduce the frequency of tumor recurrence and the subsequent need for repeated surgical debulking procedures.

Other names

autologous papilloma vaccineautologous laryngeal papilloma vaccineautogenous HPV vaccine